Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    52,428.75
    +167.05 (+0.32%)
     

  • CMC Crypto 200

    1,371.97
    +59.35 (+4.52%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Behind the brand:

'Boutique hotel at sea': Virgin Voyages CEO hails Branson's 'biggest endeavour'

On board entrepreneur's latest venture

STOCKS NEWS EUROPE-Celesio seen down as McKesson bid fails

Reuters - UK Focus

Shares in German drug distributor Celesio (Other OTC: CAKFF - news) are indicated 10.2 percent lower in pre-market trade, the worst performers on Germany's mid-cap MDAX index, as U.S. suitor McKesson (Frankfurt: MCK.F - news) says it failed to secure enough support for a planned $8.4 billion takeover of the firm.

"This result comes as somewhat of a surprise given that Celesio's two largest shareholders, Haniel and Elliott, both agreed to tender to last Thursday's sweetened 23.50 euro (per share) offer," Berenberg analysts write in a note.

Since the beginning of last year, shares in Celesio have gained more than 85 percent, boosted by prospects a takeover by McKesson, a drugs wholesaler group.

For more double click on:

Reuters messaging rm://christoph.steitz.thomsonreuters.com@reuters.net